Danaher’s share decline looks like a buying opportunity after a solid quarter

On this photograph illustration, the Danaher Company emblem seen on a smartphone with the Danaher Company inventory info within the background.

Igor Golovnev | mild rocket | Getty Photos

Life sciences and medical diagnostics firm Danaher (DHR) reported higher than anticipated earnings and gross sales for the fourth quarter. We see the value decline as unjustified and as a possibility.